CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$0.69 USD
-0.01 (-0.88%)
Updated Aug 6, 2025 03:59 PM ET
After-Market: $0.68 -0.01 (-0.79%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CANF 0.69 -0.01(-0.88%)
Will CANF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CANF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CANF
CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know
Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now
CANF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CANF
Can-Fite BioPharma (CANF) Reaches Key Enrollment Milestone in Cancer Trial
Can-Fite achieved over 50% enrollment in Phase 2a trial of Namodenoson
Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment ...
Can Fite Biofarma (CANF) Receives "Buy" Rating from Analyst | CANF Stock News
12 Health Care Stocks Moving In Monday's Intraday Session